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INTRODUCTION
The term “humanized mice” refers to immunodeficient mice 
containing human cells or tissues or to mice (immunodefi-
cient or not) that have been genetically modified to express 
human genes. Humanized mouse models are increasingly 
utilized in many areas of research, such as infectious disease, 
autoimmune disease, cancer biology, and drug develop-
ment. Because humanized mice recapitulate human physi-
ology and pathology better than traditional mouse models 
do, they are employed both in disease modeling and in pre-
clinical investigations of novel therapies. As these models are 
increasingly utilized in dermatology research, it is important 
for dermatology researchers and clinicians to have a rudi-
mentary understanding of humanized mice. In this article, 
we review the basic biology of humanized mice and provide 
examples of their use in dermatology research. 
GENERAL PRINCIPLES OF HUMANIZED MICE 
The term “humanized mice” traditionally referred to mice 
engrafted with human cells or tissues. However, advance-
ments in genetic engineering have resulted in mice geneti-
cally programmed to express human genes, also considered 
humanized mice. Therefore, humanized mice can now be 
more broadly defined as any mouse containing functional 
human proteins, cells, tissues, or organs. Overlapping vocab-
ulary has been utilized in the literature to describe humanized 
mouse models, including the terms “chimera,” “xenograft,” or 
“xenotransplant.” A chimera is an organism containing two 
or more genetically distinct cells, and the prefix “xeno” spe-
cifically refers to the combination of two species (human and 
mouse, in this case). 
Further complicating matters, a broad range of humanized 
mouse models are utilized in research, and multiple approach-
es exist to generate such models. In our view, it is easiest to 
categorically conceptualize humanized mice in three regards: 
(i) the type of “host” mouse used, (ii) the type of human cells/
tissues engrafted into that host mouse, and (iii) genetic modifi-
cations used to improve points (i) and (ii). 
CURRENTLY EMPLOYED “HOST” MICE 
Immunodeficient mice must be utilized as hosts for human cells/
tissues because the immune system of a normal (wild-type) 
mouse would reject the human cells/tissues. Multiple immunode-
ficient mouse strains have been established over time, and there is 
currently no universal immunodeficient mouse strain used for all 
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humanized mouse studies, so researchers must choose the most 
appropriate immunodeficient strain for the purpose. 
A few basic principles are common to currently employed 
immunodeficient mouse strains. First, mice must lack func-
tional T and B lymphocytes to prevent rejection of human 
cells/tissues. Some mouse strains have a genetic defect in 
recombination-activating genes (Rag) 1 or 2, which encode 
the enzymes responsible for T- and B-cell receptor rearrange-
ment. Alternatively, a genetic defect in protein kinase, DNA-
activated, catalytic polypeptide (Prkdc) results in severe 
combined immunodeficiency (SCID) mice. Rag and SCID 
mice lack mature T and B cells, but still contain functional 
natural killer cells that can destroy human cells (reviewed in 
Shultz et al., 2007). Therefore, Rag and SCID mice have been 
further modified by a targeted mutation leading to either non-
functional or a complete absence of the IL-2 receptor-γ chain 
(Il2rg). This completely inhibits natural killer–cell develop-
ment and impedes development of lymph nodes and T and 
B cells, while also potentially impairing signaling via other 
cytokines that share the Il2rg, including IL-4, -7, -9, -15, and 
-21 (reviewed in Shultz et al., 2007). Finally, immunodefi-
ADVANTAGES
• Humanized mice better recapitulate human disease 
than traditional mouse models.
• Genetic modifications can be employed to further 
“humanize” mice.
• Humanized mice can serve as preclinical models 
to test novel therapeutics; results may better reflect 
human drug metabolism, side-effect profiles, and 
efficacy. 
 
• Complete multilineage engraftment of the human 
hematopoietic system and development of memory 
T- and B-cell responses are difficult to obtain.
• Cross-reaction between coexpressed mouse and 
human factors can confound experimental results. 
• Absence of additional human factors, such as 
cytokines, homing ligands, and receptors, may limit 
accurate modeling of human physiology/pathology. 
LIMITATIONS
RESEARCH TECHNIQUES MADE SIMPLE  
2 Journal of Investigative Dermatology (2015), Volume 135 © 2015 The Society for Investigative Dermatology
cient mouse strains may also contain defects in dendritic-cell 
or macrophage function and/or in the complement system. 
The various immune defects may render a specific mouse 
strain more or less suited for a particular research study. 
Currently, the NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) and 
NOG (NODShi.Cg-PrkdcscidIL2rgtm1Sug/Jic) immunodeficient 
mouse strains are commonly employed in humanized mouse 
models owing to enhanced human cell engraftment (reviewed 
in Shultz et al., 2012). Moreover, the NSG strain is relative-
ly easy to acquire and breed. A more comprehensive list of 
immunodeficient strains used in humanized mouse models 
can be found in Shultz et al. (2007).
TYPES OF HUMAN CELLS/TISSUES ENGRAFTED
Humanized immune system
There are three basic models of humanized immune systems 
in immunodeficient mice. First, human peripheral blood 
mononuclear cells (PBMCs) or human lymphocytes from 
lymph node or spleen can be injected intravenously (most 
commonly), intraperitoneally, or intrahepatically into an 
immunodeficient mouse (reviewed in Brehm et al., 2014; 
Shultz et al., 2007, 2012). This is commonly referred to as the 
hu-PBL model. Hu-PBL is the simplest, most rapid engraft-
ment procedure of the three models. However, it results in 
engraftment of effector and memory T lymphocytes, but not 
other immune cells. Also, a xenogeneic (cross-species) graft-
versus-host disease (GVHD) ensues approximately 4 weeks 
after human cell injection, which may limit the utility of this 
model to short-term studies. Notably, GVHD researchers 
have leveraged this phenomenon into a preclinical model of 
disease (van Rijn et al., 2003). 
The second model is the transfer of human hematopoi-
etic stem cells (HSCs) into an immunodeficient mouse. This 
is commonly referred to as the Hu-HSC or Hu-CD34 meth-
od, since HSCs express and may be selected for via CD34. 
HSCs are typically isolated from fetal bone marrow, umbili-
cal cord blood or liver, or granulocyte colony-stimulating 
factor–mobilized peripheral blood (reviewed in Brehm et al., 
2014; Shultz et al., 2012). Hu-HSC results in multilineage 
hematopoiesis, although naive T cells are restricted to mouse 
rather than human major histocompatibility (MHC) groups 
(reviewed in Shultz et al., 2012). 
The third model, BLT, involves surgical implantation of 
autologous human fetal liver and thymus fragments under the 
immunodeficient mouse’s renal capsule along with transfer 
of autologous human HSCs (reviewed in Brehm et al., 2014). 
This model is the most complex, requiring technical/surgical 
expertise and a source of fetal tissue (which can be limiting). 
Because of the presence of human thymic tissue, appropri-
ate T-cell education and HLA restriction occurs (reviewed in 
Brehm et al., 2014). 
Notably, different terms are used for these models in the 
literature, which may be confusing to the reader. Originally, 
model names included “SCID” because SCID mice were 
used prior to the introduction of immunodeficient mice lack-
ing Il2rg. Also, some review articles refer to four models 
rather than three because coimplantation of human fetal liver 
and thymus was separated from the transplantation of fetal 
liver, thymus, and bone marrow (Shultz et al., 2012).
Caution is needed when reading the literature or design-
ing experiments: lineage engraftment, the ability to gener-
ate primary and secondary cellular or humoral responses, 
and T-cell restriction of each of the above models can vary 
depending on the host mouse utilized. Most publications ref-
erence experimentation performed in SCID or Rag-deficient 
mice, but outcomes may differ if NSG or NOG mice are used. 
Transplantation of nonimmune cells/tissues
In addition to immune cells, other types of human cells 
have been grafted into immunodeficient mice. For example, 
mice engrafted with human hepatocytes are increasingly 





Figure 1. Humanized mouse model demonstrates that imiquimod mobilizes and activates plasmacytoid dendritic cells to inhibit melanoma tumor growth. 
(a) Immunodeficient mice were sublethally irradiated and then injected intravenously with human CD34+ hematopoietic stem cells (HPCs), which include 
plasmacytoid dendritic cells (pDCs). Melanoma cell lines were injected subcutaneously. Mice were then treated topically (or not, control) with imiquimod, a 
TLR7/8 agonist. (b) Tumor growth was measured and compared between the mice that received imiquimod and the controls. NOD-SCID, nonobese diabetic–
severe combined immunodeficient. Reprinted from Aspord et al. (2014).
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al., 2010). Human cancer cells, either patient-derived or cell 
line–derived, are transplanted into host mice to study cancer 
biology, metastasis, and novel treatments (reviewed in Zhou 
et al., 2014). The types of human cancers studied via this 
mechanism are numerous and include both solid tumors and 
hematologic malignancies (reviewed in Zhou et al., 2014). 
Human lung, intestine, pancreatic islet, and tonsil cells have 
also been engrafted into immunodeficient mice (reviewed in 
Brehm et al., 2014). 
Human tissues and organs can be transplanted into immu-
nodeficient mice as well. In dermatology, researchers have 
capitalized on the accessibility of healthy and diseased human 
skin and straightforward surgical techniques to transplant 
human skin onto immunodeficient mice. This overcomes 
many physiologic discrepancies between mouse and human 
skin that challenges traditional mouse models. However, an 
inevitable issue with this approach is the mismatch between 
homing molecule expression on human cells and binding 
partners on murine endothelial cells that supply the transplant-
ed human skin (reviewed in Petersen and Sorensen, 2008). 
This is problematic, for example, in humanized mouse models 
of GVHD where human skin is transplanted onto immunode-
ficient mice and then human PBMCs are transferred into that 
mouse. Migration of human inflammatory cells into the skin 
graft may not reflect the types and numbers of cells that actu-
ally migrate into patient skin in GVHD. 
Genetically modified humanized mice
Genetically modified mice are revolutionizing humanized 
mouse models because they overcome limitations inherent 
to a particular model. For example, immunodeficient mice 
transgenically expressing human MHC class I and/or II have 
been generated to allow proper MHC:T-cell receptor inter-
action with engrafted human T cells. Mice transgenically 
expressing human p53, a tumor-suppressor gene, in place 
of mouse p53 were generated for cancer studies (reviewed 
in Scheer et al., 2013). Mice have been created to trans-
genically express urokinase plasminogen activator, which 
inhibits mouse hepatocyte function so that drug metabolism 
occurs only through engrafted human hepatocytes (reviewed 
in Strom et al., 2010). Ever-advancing genetic technologies 
have given researchers new freedom to push the limits of 
humanized mice (reviewed in Scheer et al., 2013).
HUMANIZED MICE IN DERMATOLOGY RESEARCH 
Humanized mice are increasingly employed in dermatology 
research. This is due in part to the ease of acquiring normal 
and diseased human skin for experimentation, of surgically 
transplanting human skin onto a mouse, and of visualizing/
assessing cutaneous disease. So far, humanized mice have 
been employed to study autoimmune/inflammatory derma-
toses such as psoriasis, alopecia areata, pemphigus vulgaris, 
GVHD, delayed-type hypersensitivity, and atopic dermatitis, 
genodermatoses such as lamellar ichthyosis, pachyonychia 
Figure 2. Novel humanized mouse model of pachyonychia congenita using 
bioengineered skin equivalents generated from patients. Skin keratinocytes 
and fibroblasts were taken from patients with pachyonychia congenita, due 
to a keratin 6A mutation, to generate bioengineered skin equivalents that 
were then grafted onto the backs of immunodeficient mice. (a) Gross image 
and (b) histology image (stained with hematoxylin and eosin) demonstrating 
clinical and pathologic characteristics of pachyonychia congenita after minor 
trauma. Reprinted from Garcia et al. (2011).
Figure 3. Genetically modified humanized mouse model to study the 
role of human anti–desmoglein 3 immunoglobulin in pemphigus vulgaris 
(PV). Human anti-desmoglein 3 (Dsg3) antibodies do not recognize mouse 
Dsg3. Therefore, mice were genetically modified to transgenically express 
human Dsg3 (hDsg3Tg) in place of mouse Dsg3 and then exposed to anti-
Dsg3 immunoglobulin from human patients with PV. (a) Humanized mouse 
mucosa demonstrates clinical erosions characteristic of PV. (b) Direct 
immunofluorescence staining shows positive staining and (c) histology 
depicts classic intraepidermal blistering characteristic of PV. Reprinted from 
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congenita, and epidermolysis bullosa, cutaneous malignan-
cies, including melanoma and squamous cell carcinoma, and 
wound healing (Aspord et al., 2014; Aufenvenne et al., 2012; 
Culton et al., 2015; Garcia et al., 2011; Gilhar et al., 2013; 
Krasagakis et al., 2001; Patel et al., 2012; reviewed in Petersen 
and Sorensen, 2008; van den Broek et al., 2014; van Rijn et 
al., 2003). The experimental approaches in these humanized 
mouse studies varied, demonstrating that, even within derma-
tologic research, humanized mouse models are diverse. 
The figures show three examples of humanized mouse 
models utilized in dermatology research. Aspord et al. (2014) 
investigated the effect of the drug imiquimod (Aldara) on mel-
anoma, utilizing a humanized mouse model in which suble-
thally irradiated immunodeficient mice were engrafted with 
CD34+ HSCs from umbilical cord blood and later injected 
subcutaneously with melanoma cell lines (Figure 1). Garcia 
et al. (2011) surgically grafted bioengineered skin equivalents 
from keratinocytes and skin fibroblasts from patients with the 
genodermatosis pachyonychia congenita onto the backs of 
immunodeficient mice to develop a preclinical model of dis-
ease (Figure 2). Culton et al. (2015) generated transgenic mice 
expressing human desmoglein 3 (Dsg3) in mice lacking Dsg3 
to study the role of anti-Dsg3 immunoglobulin in serum from 
patients with pemphigus vulgaris (Figure 3).
LIMITATIONS
Despite significant advancements made with humanized 
mice, these models are not without limitations. From a prac-
tical standpoint, the technical expertise required for some 
models can be quite advanced, and human cell/tissues, for 
example, fetal tissue, may be difficult to obtain. Purchasing, 
housing, and/or breeding host mice can be expensive. From 
a scientific perspective, there continue to be impediments to 
the development of memory T-cell responses and humoral 
immunity. Similarly, although human neutrophil, red blood 
cell, and platelet precursors engraft in mouse bone marrow, 
they do not circulate in mouse blood in any substantial num-
ber. These are in part secondary to the inability of mice to 
produce human cytokines and growth factors and, as men-
tioned above, the mismatch between homing ligands and 
receptors on human immune cells and mouse vessels (for fur-
ther discussion, see Shultz et al., 2012). Although scientists 
are working to address these limitations, it is important to 
remember that even though these mice are humanized, they 
are still mice.
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1. Hu-PBL refers to which of the following type of 
humanized mouse models:
A. Mice transplanted with fetal liver and thymus 
fragments.
B. Immunodeficient mice in which PBMCs or lym-
phocytes are transplanted with engraftment of 
mature lymphocytes.
C. Immunocompetent mice transplanted with 
human cells lacking IL-2 expression.
D. Immunodeficient mice transplanted with PBMCs 
or lymphocytes with resultant multilineage hema-
topoiesis.
2. Why are immunodeficient mice used as “hosts” for 
humanized mouse models?
A. Immunocompetent mice have dendritic cells that 
would reject human cells.
B. There is space in the host-mouse bone marrow 
for engraftment of human cells.
C. They lack T, B, and natural killer cells that would 
otherwise reject human cells.
D. Their inability to signal through IL-4, -7, -9, -15, 
and -22 prevents rejection of human cells.
3. What immunodeficient strains are most commonly 
employed for humanized mouse models?
A. SCID and nude mice.
B. Rag and nude mice.
C. NSG and NOG mice.
D. NSG and Rag mice.
4. Humanized mouse models have been used in which of 
the following areas of dermatologic research?
A. Pemphigus vulgaris and other autoimmune dis-
eases.
B. Wound healing.
C. Squamous cell carcinoma and other cutaneous 
malignancies.
D. All of the above.
5. Which is true of humanized mouse models?
A. They are diverse and in constant development.
B. The term refers to mice containing functional 
human proteins, cells, tissues, and organs.
C. They may also be called “human–mouse chime-
ras” or “xenotransplants” in the case of mice con-
taining human cells or tissues.
D. All of the above.
QUESTIONS
This article has been approved for 1 hour of Category 1 CME credit. To 
take the quiz, with or without CME credit, follow the link under the “CME 
ACCREDITATION” heading.
For each question, more than one answer may be correct.
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SUPPLEMENTARY MATERIAL 
A PowerPoint slide presentation appropriate for journal club or other teaching 
exercises is available at http://dx.doi.org/10.1038/jid.2015.393.
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